Lausanne – January 9th, 2013 – Debiopharm Group (Debiopharm) and Spinomix SA, a Swiss company advancing molecular diagnostic technologies, announced the closing of a Series A equity investment of $ 3 Million. The financing round was led by Debiopharm Group™. Significant participation and support is being provided by existing investors and a private US investor group with proven entrepreneurial experience. Debiopharm is a successful drug development company based in Switzerland which is active in the field of molecular diagnostics and has completed several equity rounds in diagnostic start-ups.
Spinomix focuses on delivering high-quality-low-cost solutions for sample preparation of biological materials. The extraction and concentration of targeted cells and molecules (e.g. bacteria and DNA) under routine conditions, of adequate quality and at optimal cost are critical for their detection on existing and future in vitro diagnostic platforms. Spinomix’s approaches use two proprietary technologies: MagPhase™, an automated sample preparation platform based on magnetic nanoparticles and microfluidics with cost efficient, rapidly processed and disposable cartridges. FibroTrap™, a fibrinogen based technology, to separate targeted cells and molecules within routine sample collection tubes.